The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 363:288-290 July 15, 2010 Number 3
NextNext

Drug Management of Obesity — Efficacy versus Safety
Arne Astrup, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Disclosures
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Smith, S. R.
The history of pharmacologic treatment of obesity is characterized by repetition: most drugs that have achieved regulatory approval and reached the markets have subsequently been withdrawn owing to postmarketing discovery of serious adverse effects. In 2007, the cannabinoid-receptor antagonist rimonabant was not approved by the Food and Drug Administration (FDA) and was withdrawn from the market in Europe because of an increased risk of depression, anxiety, and suicidal ideation1; the development program for several compounds of the same class that were in phase 3 studies had to be terminated. In January of this year, the European Medicine Agency's Committee . . . [Full Text of this Article]


Source Information

From the Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, Frederiksberg, Denmark.




HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.